Drug Profile
NV VPAC1
Alternative Names: 64Cu-TP-3805; Cu64-Cu67-NV-VPAC1; Cu64-NLS-VPAC1; Cu64-TP 3805; Ga68-NLS-VPAC1; NLS-VPAC1; NV-VPAC1; TP3805Latest Information Update: 05 Jan 2024
Price :
$50
*
At a glance
- Originator Thomas Jefferson University
- Developer National Institutes of Health (USA); Naviscan PET Systems; NuView Life Sciences; Thomas Jefferson University
- Class Antineoplastics; Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Breast cancer; Prostate cancer; Urogenital cancer
- Preclinical Cancer